WAVE LIFE SCIENCES LTD
WVENASDAQTrading Snapshot
- Day Range
- $724.56 – $741.94
- 52-Week Range
- $5.02 – $21.73
- Volume
- $3.08B
- Avg Volume
- $3.54B
- Shares Outstanding
- 192.4M
- Next Earnings
- Sep 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $43M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 18.4x
- EPS (TTM)
- $-1.09
- Dividend Yield
- —
Why Investors Own WVE
- ✓High-growth profile — revenue up +34.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About WAVE LIFE SCIENCES LTD
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Prime Medicine: An Initial Prognosis
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Bank of America SMID Cap Virtual Conference August 11, 2026 1:00 PM EDTCompany ParticipantsPaul Bolno - President, CEO &...
Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?
Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a year earlier and a wider net loss of US$69.36 million, while first-half 2026 sales rose to US$40.52 million from US$17.87 million and net loss narrowed slightly to US$95.44 million. The company also completed court and shareholder approvals to shift its corporate domicile from Singapore to the United States, a corporate restructuring that could affect its regulatory framework,...
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approvals required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arran
Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $27 to $23.
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in August. BofA Securities 2026 SMID Cap Executive Insights EventDate: Tuesday, August 11, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in